Titan Spine initiates full US launch of new NanoLock surface technology

Titan Spine's NanoLock surface up close
Titan Spine’s NanoLock surface up close

Titan Spine has expanded the distribution of its line of Endoskeleton titanium implants featuring the company’s new proprietary NanoLock surface technology to all of the USA. The launch follows the alpha introduction of the NanoLock technology initiated recently in a limited number of sites. The company has sold NanoLock implants to 14 hospitals in eight states since its introduction. According to a press release, the company is in the process of signing contracts with several large hospital systems.

NanoLock was recently granted its own new technology category and code, formally known as an “ICD-10pcs New Technology Section X Code,” by the US Centers for Medicare & Medicaid Services (CMS).

Kevin Gemas, president of Titan Spine, comments, “NanoLock [is] the only nano-cleared interbody device on the market and is the only interbody device that has access to the recently-created new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Through our extensive research, which has been published in several peer-reviewed journals, the industry is now beginning to understand the importance of our very specific titanium nano-architecture in its ability to promote the generation of osteogenic and angiogenic growth factors necessary for bone growth and fusion compared to other surfaces. And finally, we appointed a general counsel to protect our legal interests and ensure that our extensive intellectual property portfolio and proprietary scientific data are fully defended.”

Titan Spine offers a full line of Endoskeleton devices that feature Titan Spine’s proprietary NanoLock surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and nano levels. This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins, downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.